One in five people are carrying it. It takes one blood test, one time, ever. And it's almost certainly not on your chart.

Meet the cholesterol nobody told you about

You know LDL. It's the "bad cholesterol" your doctor circles on your lab report. You know HDL, the "good" one. You've probably been told to eat better, move more, and watch your numbers.

Now meet the one that ignores all of that.

It's called lipoprotein(a). Everyone says it out loud as "L P little a." It's a cholesterol particle that looks a lot like LDL but has an extra protein stuck to it, like someone welded a trailer hitch onto a sedan. That extra part changes everything. It makes the particle stickier inside your arteries, more likely to cause inflammation, and more likely to help form clots.

Here's the part that stings: your Lp(a) level is set by a single gene. More than 90 percent of the difference between you and your neighbor comes down to DNA. You were born with your number. You will die with roughly the same number.

Diet doesn't move it. Exercise doesn't move it. Losing weight doesn't move it. Quitting smoking, which is genuinely one of the best things a human can do for their heart, does not move it.

Your kale is doing a lot of good things. This is not one of them.

Your cholesterol medication probably doesn't touch it either

This is where it gets genuinely annoying.

A 2025 meta analysis pulled together 147 randomized trials covering more than 145,000 people to see which drugs actually lower Lp(a). The results:

So the most commonly prescribed cholesterol drug on Earth, the one millions of people take specifically to protect their hearts, does essentially nothing to this particular risk.

About niacin: yes, it lowers Lp(a). No, you should not take it for that. Trials of niacin failed to reduce heart attacks and it comes with real side effects. Guidelines specifically do not recommend it, or hormone therapy, for lowering Lp(a) risk. Please don't go buy a bottle at the pharmacy because of a table you read on the internet.

About one in five people have a high level

Roughly 20 percent of people have an Lp(a) at or above the level considered high. In people of African ancestry, it's closer to 30 percent.

The risk climbs steadily as the number climbs. Using the numbers from the 2026 American College of Cardiology and American Heart Association guideline:

• Around 50 mg/dL (about 125 nmol/L): roughly 40 percent higher lifetime risk of heart attack and related events.

• Around 80 to 100 mg/dL: risk roughly doubles.

• Around 180 mg/dL: risk is about four times higher. That's in the same neighborhood as inheriting familial hypercholesterolemia, a condition serious enough that doctors screen entire families for it.

It also raises your odds of aortic stenosis, which is when the main valve out of your heart stiffens and narrows. That one often needs surgery.

So this is not a rounding error. If you're in the 20 percent, your actual risk is meaningfully different from what your habits, your BMI, and your normal LDL would suggest. You could be doing everything right and still be walking around with a loaded risk factor you've never heard of.

A quick, extremely practical warning about units

Lp(a) gets reported two different ways, and they are not interchangeable.

• mg/dL measures the weight of the particles.

• nmol/L measures the number of particles.

You will see conversion factors online. Ignore them. They don't reliably work, because Lp(a) particles come in wildly different sizes from person to person. A big heavy particle and a small light one both count as "one particle," but they weigh very different amounts.

Ask your lab for the result in nmol/L using an isoform insensitive assay. That phrase sounds intimidating but you can just say it, or write it down and hand it over. It means the test counts particles and isn't fooled by particle size. It's the more accurate way to measure this.

When not to get tested

The "test once, forever" idea is mostly true, with a few real exceptions. Lp(a) can temporarily rise or fall when something else is going on in your body:

• Kidney disease, especially nephrotic syndrome, pushes it up.

• Untreated hypothyroidism pushes it up.

• Active infection or inflammation can push it up, because Lp(a) behaves partly like an inflammatory marker.

• Serious liver disease pushes it down.

• Pregnancy and menopause shift it.

Translation: don't get this test in the middle of the flu, and if you have kidney, thyroid, or liver problems, mention that to your doctor. A borderline result under those conditions may be worth repeating once things settle down.

The timing on this is genuinely unusual

For decades, doctors had a good reason to skip this test: even if your number was high, there was nothing to do about it. Knowing felt like reading a weather forecast for a planet you can't visit.

Two things changed.

First, the guidelines caught up. The 2026 ACC/AHA multisociety dyslipidemia guideline now gives a Class 1 recommendation, their strongest tier, that every adult should have Lp(a) measured at least once in their lifetime. It also recommends cascade testing, meaning if yours is high, your parents, siblings, and children should get checked too. This is a genetic condition. It runs in families. Finding it in yourself finds it in them.

Second, an entire new class of drugs is in final testing. These are not supplements. They are engineered medicines that shut down production of the Lp(a) protein in your liver.

• Pelacarsen, a monthly injection, lowers Lp(a) by roughly 54 percent compared to placebo in the most recent network analysis. (You may see "80 to 90 percent" quoted for pelacarsen online. That's inflated. The bigger drops belong to the drugs below.)

• Olpasiran, given a few times a year, drops it around 92 percent.

• Zerlasiran, similar schedule, around 81 percent.

• Lepodisiran, also in the very high range.

• Muvalaplin, a once daily pill, around 77 percent. A pill matters, because a lot of people who will happily swallow something daily will not happily inject themselves.

The big one to watch is Lp(a)HORIZON. It's testing pelacarsen in 8,323 people who already have heart disease and an Lp(a) of 70 mg/dL or higher. It runs until 993 heart events have occurred, which takes about six years. First results are expected around 2026. It is the first trial ever built to answer the question everyone's been asking for thirty years.

There's also one fresh piece of evidence from 2026. In the Lp(a)FRONTIERS APHERESIS trial, pelacarsen cut Lp(a) by 72 percent and nearly eliminated the need for lipoprotein apheresis in patients who had been dependent on it. Apheresis is a procedure where they filter your blood through a machine, roughly every two weeks, sometimes for years. Getting people off that is a real, meaningful, life-changing result. It's still not proof that fewer people have heart attacks, but it's the first randomized evidence of a consequence you can actually feel.

The honest caveat, stated plainly

Nobody has yet proven that lowering Lp(a) prevents heart attacks.

We know high Lp(a) causes heart disease. Genetic studies settled that. But causing a problem and being fixable by reversing it are two different things, and medicine has been embarrassed before by assuming otherwise. That is precisely what Lp(a)HORIZON and its sibling trials are designed to determine.

So a high result today does not mean a prescription tomorrow.

So what do you actually do if it comes back high?

This is the part most articles skip, and it's the part that matters, because "wait for a drug" is not a plan. If your Lp(a) is elevated, here is what your doctor can act on right now:

• Get everything else lower than average. You can't lower Lp(a) yet, but you can lower LDL and apoB harder, and that reduces your total burden. High Lp(a) is formally a "risk enhancer," which is doctor speak for "treat this person more aggressively than the calculator says."

• Take blood pressure seriously. Same logic. Reduce the risks you can while you can't reduce this one.

• Consider a coronary calcium scan. It's a quick CT that shows whether plaque has actually built up in your heart's arteries. A high Lp(a) tells you about risk. A calcium score tells you what has already happened. Together they're far more useful than either alone.

• Tell your family. Cascade testing is in the guideline for a reason. Your siblings and your kids have a meaningful chance of carrying the same gene, and they have more years ahead to do something about it.

• Ask about aortic valve monitoring if your number is very high, since Lp(a) drives valve stiffening as well as artery disease.

• Get on the list. Ask your doctor to flag it in your chart. If these drugs get approved, the people who already know their number will be first in line.

And if it comes back normal?

Then you've closed the question permanently, for about forty dollars, and you never need to think about it again.

One caveat so nobody gets overconfident: a normal Lp(a) does not mean you're safe from heart disease. It means this specific hidden risk isn't yours. Your LDL, blood pressure, blood sugar, and everything else still matter exactly as much as they did yesterday.

The whole point, in one paragraph

Lp(a) is not a lifestyle problem, so a lifestyle answer was never going to solve it. It's a gene you were handed at birth, it affects one in five people, it's invisible on a standard lipid panel because nobody orders it, and for the first time in medical history there are real drugs in final testing aimed directly at it.

One test. Once. No fasting. Never repeated.

That's not a treatment. It's a question, and the answer decides whether any of this ever applies to you.

This is general health information, not medical advice. Talk to your doctor about whether and when to test, and bring this with you if it helps start the conversation.

Mach, F., Koskinas, K. C., & Roeters van Lennep, J. E. (2025). 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal.

Nordestgaard, B. G., & Langsted, A. (2024). Lipoprotein(a) and cardiovascular disease. The Lancet, 404(10459), 1255-1264. https://doi.org/10.1016/s0140-6736(24)01308-4

Blumenthal, R. S., Morris, P. B., & Gaudino, M. (2026). 2026 ACC/AHA guideline on the management of dyslipidemia. Journal of the American College of Cardiology.

Xie, S., Galimberti, F., Olmastroni, E., Carugo, S., Catapano, A. L., & Casula, M. (2025). Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials. Atherosclerosis, 408, 120420. https://doi.org/10.1016/j.atherosclerosis.2025.120420

Koschinsky, M. L., Bajaj, A., Boffa, M. B., Dixon, D. L., Ferdinand, K. C., Gidding, S. S., Gill, E. A., Jacobson, T. A., Michos, E. D., Safarova, M. S., Soffer, D. E., Taub, P. R., Wilkinson, M. J., Wilson, D. P., & Ballantyne, C. M. (2024). A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. Journal of Clinical Lipidology, 18(3), e308-e319. https://doi.org/10.1016/j.jacl.2024.03.001

Sahebkar, A., Simental-Mendía, L. E., Watts, G. F., Serban, M. C., & Banach, M. (2017). Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Medicine, 15(1). https://doi.org/10.1186/s12916-017-0787-7

Wiggins, B. S., Barac, A., & Benziger, C. P. (2026). 2026 dyslipidemia guideline-at-a-glance. Journal of the American College of Cardiology.

Mora, S., & Kronenberg, F. (2025). Lipoprotein(a). JAMA, 333(21), 1918-1919. https://doi.org/10.1001/jama.2025.2373

Tsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., Moriarty, P. M., Rader, D. J., Remaley, A. T., Reyes-Soffer, G., Santos, R. D., Thanassoulis, G., Witztum, J. L., Danthi, S., Olive, M., & Liu, L. (2018). NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Journal of the American College of Cardiology, 71(2), 177-192. https://doi.org/10.1016/j.jacc.2017.11.014

Tsimikas, S., & Marcovina, S. M. (2022). Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds. Journal of the American College of Cardiology, 80(9), 934-946. https://doi.org/10.1016/j.jacc.2022.06.019

Cho, L., Nicholls, S. J., Nordestgaard, B. G., Landmesser, U., Tsimikas, S., Blaha, M. J., Leitersdorf, E., Lincoff, A. M., Lesogor, A., Manning, B., Kozlovski, P., Cao, H., Wang, J., & Nissen, S. E. (2025). Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). American Heart Journal, 287, 1-9. https://doi.org/10.1016/j.ahj.2025.03.019

Tomlinson, B., & Law, C. F. (2025). Lipoprotein(a) – treatments in development. Expert Opinion on Pharmacotherapy, 26(17), 1831-1839. https://doi.org/10.1080/14656566.2025.2601062

Wu, A. X., Wang, X. J., Zhao, C., Hu, J. Q., Li, J. W., Xu, Y., Li, Y., & Liu, S. (2026). Comparative efficacy and safety of novel Lp(a)-lowering therapies for ASCVD prevention: A network meta-analysis. Pharmacological Research, 227, 108178. https://doi.org/10.1016/j.phrs.2026.108178

O’Donoghue, M. L., Rosenson, R. S., López, J. A. G., Lepor, N. E., Baum, S. J., Stout, E., Gaudet, D., Knusel, B., Kuder, J. F., Murphy, S. A., Wang, H., Wu, Y., Shah, T., Wang, J., Wilmanski, T., Sohn, W., Kassahun, H., & Sabatine, M. S. (2024). The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering. Journal of the American College of Cardiology, 84(9), 790-797. https://doi.org/10.1016/j.jacc.2024.05.058

Parhofer, K. G., Julius, U., Herzog, A. L., Krüger, T., Weinmann-Menke, J., Heine, G. H., Cao, H., Schorr, J., Ferber, P., Wang, J., Cristante, E., Müller-Edenborn, B., Vogt, A., Schettler, V., & Steinhagen-Thiessen, E. (2026). Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. European Heart Journal, 47(25), 3284-3294. https://doi.org/10.1093/eurheartj/ehag073

Santana, A. U. L., Yusufzai, M. O., & Freitas, A. P. S. (2026). Efficacy and safety of novel lipoprotein(a)-targeted therapies: A systematic review and meta-analysis of randomised controlled trials. Diabetes, Obesity and Metabolism.

Agarwala, A., Ballantyne, C., & Stone, N. J. (2023). Primary Prevention Management of Elevated Lipoprotein(a). JAMA Cardiology, 8(1), 96-97. https://doi.org/10.1001/jamacardio.2022.4063